Skip to main content
    A

    AngioDynamics Inc (ANGO)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $11.58
    +0.53 (+4.80%)

    Market Cap: $464.70M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    73%(29/40)
    Avg Surprise
    -343.68%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Nov 30, 2026
    EPS Consensus$-0.07
    Range$-0.10 - $-0.02
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.05-49.9%
    60d ago$-0.08+16.0%
    30d ago$-0.08+16.0%
    7d ago$-0.08+16.0%
    Current$-0.07
    Revenue Consensus
    $84M
    Range$82M - $85M
    4 analysts
    Period ending Feb 28, 2027
    EPS Consensus$-0.08
    Range$-0.10 - $-0.06
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.03-206.8%
    60d ago$-0.06-27.8%
    30d ago$-0.06-27.8%
    7d ago$-0.06-27.8%
    Current$-0.08
    Revenue Consensus
    $83M
    Range$82M - $85M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    May 27EST
    		-$-0.02---
    Feb 27EST
    		-$-0.08---
    Nov 26EST
    		-$-0.07---
    Aug 26
    Reported Oct 8
    		$-0.04N/A+60.00%Beat+60.0%
    May 26
    Reported Jul 14
    		$-0.07$-0.11+36.36%Beat-133.3%
    Feb 26
    Reported Apr 2
    		$0.02N/A+118.18%Beat-33.3%
    Nov 25
    Reported Jan 6
    		$-0.15$-0.10-52.90%Miss-282.3%
    Aug 25
    Reported Oct 2
    		$-0.10$-0.12+16.67%Beat+9.1%
    May 25
    Reported Jul 15
    		$-0.03N/A+75.00%Beat+50.0%
    Feb 25
    Reported Apr 2
    		$0.03N/A+123.08%Beat+118.8%
    Nov 24
    Reported Jan 8
    		$-0.04N/A+63.64%Beat+20.0%
    Aug 24
    Reported Oct 3
    		$-0.11$-0.15+26.67%Beat+8.3%
    May 24
    Reported Jul 16
    		$-0.06N/A+64.71%Beat-400.0%
    Feb 24
    Reported Apr 4
    		$-0.16$-0.15-6.67%Miss-433.3%
    Nov 23
    Reported Jan 5
    		$-0.05$-0.07+28.57%Beat-600.0%
    Aug 23
    Reported Oct 4
    		$-0.12$-0.13+7.69%Beat-100.0%
    May 23
    Reported Jul 12
    		$0.02$0.02+0.00%Beat+100.0%
    Feb 23
    Reported Mar 30
    		$-0.03$-0.01-200.00%Miss-200.0%
    Nov 22
    Reported Jan 5
    		$0.01$-0.01+200.00%Beat+150.0%
    Aug 22
    Reported Oct 6
    		$-0.06$-0.02-200.00%Miss-200.0%
    May 22
    Reported Jul 12
    		$0.01$0.01+0.00%Beat+102.0%
    Feb 22
    Reported Apr 7
    		$0.03$-0.01+400.00%Beat+50.0%
    Nov 21
    Reported Jan 6
    		$-0.02$0.01-300.00%Miss-300.0%
    Aug 21
    Reported Sep 30
    		$-0.02$-0.04+50.00%Beat-200.0%
    May 21
    Reported Jul 13
    		$-0.51$-0.00-15212.12%Miss-742.2%
    Feb 21
    Reported Mar 30
    		$0.02$-0.02+200.00%Beat+100.0%
    Nov 20
    Reported Jan 7
    		$0.01$-0.02+150.00%Beat-83.3%
    Aug 20
    Reported Sep 29
    		$0.02N/A+128.57%Beat-75.0%
    May 20
    Reported Jul 16
    		$-0.06$-0.06+0.00%Beat-124.0%
    Feb 20
    Reported Apr 7
    		$0.01N/A+133.33%Beat-94.7%
    Nov 19
    Reported Jan 7
    		$0.06$0.02+200.00%Beat-72.7%
    Aug 19
    Reported Oct 3
    		$0.08$0.04+100.00%Beat-50.0%
    May 19
    Reported Jul 10
    		$0.25$0.26-3.85%Miss+25.0%
    Feb 19
    Reported Apr 2
    		$0.19$0.22-13.64%Miss-24.0%
    Nov 18
    Reported Jan 4
    		$0.22$0.21+4.76%Beat+37.5%
    Aug 18
    Reported Sep 27
    		$0.16$0.18-11.11%Miss+33.3%
    May 18
    Reported Jul 11
    		$0.20$0.21-4.76%Miss+5.3%
    Feb 18
    Reported Mar 29
    		$0.25$0.19+31.58%Beat+31.6%
    Nov 17
    Reported Jan 4
    		$0.16$0.16+0.00%Beat-15.8%
    Aug 17
    Reported Sep 28
    		$0.12$0.16-25.00%Miss-
    May 17
    Reported Jul 18
    		$0.19$0.16+18.75%Beat-
    Feb 17
    Reported Mar 30
    		$0.19$0.15+26.67%Beat-
    Nov 16
    Reported Jan 6
    		$0.19$0.16+18.75%Beat-

    Key Metrics

    Valuation
    P/E Ratio-47.67EV/EBITDAN/A
    Price/FCF-103.51xFCF Yield-0.97%
    Profitability
    Profit Margin-10.10%Operating Margin-7.81%
    ROE-19.20%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio2.40xQuick Ratio1.48x
    Trading Statistics
    Beta0.30Avg Volume961.33K
    52-Week High$16.2952-Week Low$9.39

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$12.69
    SMA 20$14.07
    SMA 50$15.01
    SMA 200$12.44
    EMA 10$12.41
    EMA 20$13.44
    EMA 50$14.22
    EMA 200$13.01

    MACD

    Line: -1.10Signal: -0.69Hist: -0.41

    ADX

    ADX: 38.8+DI: 6.7-DI: 39.0

    Aroon & PSAR

    Aroon Up16.0
    Aroon Down92.0
    PSAR$13.59

    Bollinger Bands

    Upper Band$17.90
    Lower Band$10.24
    %B Position5441%(Upper)
    Band Width0.17

    RSI (14-Day)

    Oversold
    28.4

    Momentum Oscillators

    Stoch %K10.8
    Stoch %D9.6
    Williams %R-81.3
    ROC (10d)-23.4%
    Momentum-3.54
    CCI (20d)-110.9
    MFI (14d)33.0

    Volatility Measures

    ATR (14d)$0.74(6.4%)
    StdDev (20d)1.91
    Hist Vol83.9%(High)

    Volume Flow

    VWAP$11.42
    OBV3.9M
    AD Line-5.9M
    CMF (20d)-0.124

    Volume Metrics

    Avg Vol (20d)1.0M
    Vol Ratio1.1x
    VWMA (20d)$13.17

    Pivot Points

    R3$12.19
    R2$11.84
    R1$11.44
    Pivot Point$11.09
    S1$10.69
    S2$10.34
    S3$9.94

    Advanced Oscillators

    TSI-47.70
    Ultimate Osc33.4
    KST-161.66

    Financial Data

    QuarterAug 2026May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024Nov 2023
    Total Revenue$80.92M$86.61M$78.42M$79.43M$75.71M$80.16M$72.00M$72.84M$67.49M$70.98M$75.18M$79.07M
    Cost of Revenue$32.88M$39.83M$36.94M$34.65M$33.85M$37.94M$33.15M$32.94M$30.77M$32.47M$39.32M$38.81M
    Gross Profit$48.04M$46.77M$41.48M$44.78M$41.86M$42.22M$38.86M$39.91M$36.72M$38.52M$35.86M$40.26M
    Operating Expenses$55.34M$56.97M$54.43M$50.91M$52.51M$48.01M$48.83M$51.00M$49.82M$52.96M$235.76M$53.38M
    R&D$7.98M$8.18M$7.08M$7.77M$6.42M$6.59M$6.91M$6.43M$6.29M$6.72M$8.19M$8.66M
    SG&A$12.47M$10.27M$10.72M$10.15M$12.55M$10.24M$10.49M$10.39M$10.97M$10.44M$10.58M$9.29M
    Operating Income$-7,302,000$-10,195,000$-12,951,000$-6,125,000$-10,656,000$-5,788,000$-9,974,000$-11,094,000$-13,098,000$-14,449,000$-199,896,000$-13,120,000
    Interest Income$-88,000$-105,000$-88,000$-102,000$-4,000$3,000$135,000$234,000$606,000$567,000$394,000$534,000
    Interest Expense$0$840,000$0$230,000$182,000$322,000$0$0$0$0$0$0
    Income Before Tax$-7,296,000$-11,035,000$-8,072,000$-6,355,000$-10,838,000$-6,110,000$-4,409,000$-10,848,000$-12,665,000$-14,141,000$-199,740,000$-12,618,000
    Income Tax Expense$-199,000$370,000$12,000$-5,000$65,000$-60,000$-2,000$-110,000$133,000$-692,000$-12,004,000$16.43M
    Net Income$-7,097,000$-11,405,000$-8,084,000$-6,350,000$-10,903,000$-6,050,000$-4,407,000$-10,738,000$-12,798,000$-13,449,000$-187,736,000$-29,048,000
    EBITDA$-1,710,000$-5,333,000$-2,393,000$-506,000$-4,884,000$-280,000$1.77M$-4,219,000$-6,486,000$-7,891,000$-192,612,000$-6,467,000
    EBIT$-7,208,000$-10,930,000$-7,984,000$-6,253,000$-10,834,000$-6,113,000$-4,544,000$-11,082,000$-13,271,000$-14,708,000$-200,134,000$-13,152,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ANGO

    Government Contracts

    Gov Obligations (TTM)
    -$2434
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Humana applies Medicare coverage rules to a non-heat treatment for some prostate and liver cancer patients.

    Humana has updated its Medicare Advantage policy to cover AngioDynamics' NanoKnife System for eligible patients with intermediate-risk prostate cancer and certain liver tumors, effective October 1...

    Stock Titan•10/15/26•Bullish

    AngioDynamics Q1 revenue rises 6.9%, but shares drop 21% despite positive results and CEO change.

    AngioDynamics reported a 6.9% increase in Q1 fiscal 2027 revenue to $80.9 million and a narrowed adjusted loss...

    Pluang•10/14/26•Neutral

    HC Wainwright & Co. maintains Buy rating on AngioDynamics, $18 price target

    HC Wainwright & Co. has reiterated its Buy rating for AngioDynamics (ANGO), setting an $18 price target, which suggests a 57.9% upside from its recent closing price. The firm's positive outlook is based on AngioDynamics'...

    TradingView•10/13/26•Bullish

    Teleconferência de Resultados do 1º Trimestre Fiscal de 2027 da AngioDynamics (ANGO): Receita de MedTech Cresce 13,2%

    AngioDynamics reported a 6.9% increase in Q1 FY2027 revenue to $80.9 million, driven by a 13.2% rise in its Med Tech segment. Key growth drivers included the Auryon and NanoKnife platforms...

    TradingKey•10/11/26•Bullish

    ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y

    AngioDynamics (ANGO) reported a narrower-than-expected loss per share and an increase in revenues for Q1 fiscal 2027, driven primarily by strong performance in its Med Tech segment. The company's Med Tech products...

    TradingView•10/9/26•Somewhat-Bullish

    ANGO Valuation and Fair Value

    P/E
    -47.7x
    Forward P/E
    96.2x
    P/FCF
    -103.5x
    PEG
    1.4x
    P/B
    3.0x
    See GNG's fair value

    ANGO Profitability: Margins, ROIC and FCF

    Gross margin
    55.7%
    Operating margin
    -7.8%
    Net margin
    -10.1%
    ROE
    -19.2%
    FCF margin
    -1.4%
    FCF yield
    -1.0%

    ANGO Competitors

    CompanyTicker
    Senseonics Holdings, Inc. Common StockSENS
    Tilray IncTLRY
    XOMA CorpXOMA
    Brainsway LtdBWAY
    Evotec SE ADREVO
    National Research CorpNRC
    Regenxbio IncRGNX
    Cerus CorporationCERS

    Sector: Healthcare

    ANGO Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    0
    Buy
    4
    Hold
    0
    Sell
    0
    Strong Sell
    0

    ANGO Bull Case vs Bear Case

    Bull case

    • ANGO beat EPS estimates in 87.5% of its last 8 reported quarters.

    Bear case

    • ANGO has a -10.1% net profit margin.

    ANGO Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    55.0%
    EPS estimate (fiscal period ending Nov 30, 2026)
    $-0.07
    Estimate revisions (30 days, fiscal period ending Nov 30, 2026)
    1 up, 1 down

    Frequently Asked Questions About ANGO

    Does ANGO pay dividends?

    AngioDynamics Inc (ANGO) does not currently pay a regular dividend.

    What is ANGO's market cap?

    AngioDynamics Inc (ANGO) has a market capitalization of $464.70M with a current stock price of $11.58.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In